- Home
- RCUS vs COLL Comparison
RCUS vs COLL Comparison
Compare RCUS & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- COLL
- Stock Information
- Founded
- RCUS 2015
- COLL 2002
- Country
- RCUS United States
- COLL United States
- Employees
- RCUS N/A
- COLL N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- RCUS Health Care
- COLL Health Care
- Exchange
- RCUS Nasdaq
- COLL Nasdaq
- Market Cap
- RCUS 906.4M
- COLL 958.8M
- IPO Year
- RCUS 2018
- COLL 2015
- Fundamental
- Price
- RCUS $9.60
- COLL $32.19
- Analyst Decision
- RCUS Buy
- COLL Strong Buy
- Analyst Count
- RCUS 8
- COLL 4
- Target Price
- RCUS $20.86
- COLL $43.75
- AVG Volume (30 Days)
- RCUS 891.1K
- COLL 269.6K
- Earning Date
- RCUS 08-07-2025
- COLL 08-07-2025
- Dividend Yield
- RCUS N/A
- COLL N/A
- EPS Growth
- RCUS N/A
- COLL N/A
- EPS
- RCUS N/A
- COLL 1.25
- Revenue
- RCUS $141,000,000.00
- COLL $664,283,000.00
- Revenue This Year
- RCUS N/A
- COLL $20.23
- Revenue Next Year
- RCUS $28.73
- COLL $3.82
- P/E Ratio
- RCUS N/A
- COLL $25.26
- Revenue Growth
- RCUS N/A
- COLL 17.17
- 52 Week Low
- RCUS $6.50
- COLL $23.23
- 52 Week High
- RCUS $18.98
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- RCUS 53.46
- COLL 52.81
- Support Level
- RCUS $9.14
- COLL $30.75
- Resistance Level
- RCUS $9.62
- COLL $32.47
- Average True Range (ATR)
- RCUS 0.44
- COLL 0.87
- MACD
- RCUS 0.04
- COLL -0.12
- Stochastic Oscillator
- RCUS 62.85
- COLL 42.65
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.